Assertio Holdings to Acquire Spectrum Pharmaceuticals for ~$291M
Shots:
- Spectrum stockholders will receive up front of 0.1783 ASRT shares per SPPI share ($1.14/share) representing a premium of 65% plus one CVR per Spectrum share for total consideration of ~$1.34/share & an additional $0.20/share (~$43M) in cash or stock at Assertio's election for $1.34 ($291M) representing a premium of 94% to Spectrum’s latest closing price. The acquisition is expected to close in Q3’23
- Assertio stockholders to own ~65% & Spectrum stockholders will own ~ 35% of combined company. Spectrum’s combined assets & commercial infrastructure will accelerate Rolvedon’s launch for patients' benefit & drive further growth
- The combination of Assertio’s Omni-Channel digital sales capabilities & Rolvedon's in-person commercial team will enhance market access & growth across all products
Ref: Globenewswire | Image: Assertio
Related News:- Collegium to Acquire US Rights of Assertio's Nucynta Franchise for $375M
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.